Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

NCT00424515 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Mucosal Melanoma
Acral/Lentiginous Melanoma
Chronically Sun Damaged Melanomas

Interventions

DRUG: Imatinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]